Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mtibaa M, Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Olivenstein R
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Dove Medical Press 2021-12-01
Colecção:	ClinicoEconomics and Outcomes Research
Assuntos:	moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma
Acesso em linha:	https://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEOR
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!